Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis

Rheumatology

Volumn 45, Issue 7, 2006, Pages 815-818

  Ogawa, F ^a   Shimizu, K ^a   Muroi, E ^a   Hara, T ^a   Hasegawa, M ^b   Takehara, K ^b   Sato, S ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

8 isoprostane; Immunological abnormalities; Oxidative stress; Pulmonary fibrosis; Renal vascular damage; Systemic sclerosis

Indexed keywords

8 ISOPROSTANE; ARACHIDONIC ACID; AUTOANTIBODY; CARBON MONOXIDE; FREE RADICAL; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ARTICLE; BLOOD VESSEL INJURY; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSE SCLERODERMA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOLOGY; IN VIVO STUDY; KIDNEY BLOOD VESSEL; LIMITED SCLERODERMA; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

ADULT; AGED; BIOLOGICAL MARKERS; CARBON MONOXIDE; DINOPROST; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DIFFUSING CAPACITY; RENAL CIRCULATION; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; VASCULAR RESISTANCE; VITAL CAPACITY;

EID: 33745620189     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel012     Document Type: Article

References (25)

1. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21:1477-83.
2. Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44:2653-64.
3. Emerit I, Filipe P, Meunier P et al. Clastogenic activity in the plasma of scleroderma patients: A biomarker of oxidative stress. Dermatology 1997;194:140-6.
4. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
5. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 2002;41: 843-7.
6. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998;25:314-17.
7. Mazzone A, Cusa C, Bucci L et al. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 1999;29:1-5.
8. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43:1085-93.
9. Sud A, Khullar M, Wanchu A, Bambery P. Increased nitric oxide production in patients with systemic sclerosis. Nitric Oxide 2000; 4:615-19.
10. Kahaleh MB, Pan-Sheng F, Cerinic MM, Stefanovic Racic M, Ignarro L. Study of endothelial dependent relaxation in scleroderma. Arthritis Rheum 1993;36(Suppl.): B233.
11. Ignarro LJ. Endothelium-derived nitric oxide: Actions and properties. FASEB J 1989;3:31-6.
12. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: A chemist's perspective. Trends Pharmacol Sci 1995;16:18-22.
13. Suematsu M, Wakabayashi Y, Ishimura Y. Gaseous monoxides: A new class of microvascular regulator in the liver. Cardiovasc Res 1996;32:679-86.
14. Morrow JD, Roberts LJ 2nd. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996;51:1-9.
15. Morrow JD, Frei B, Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
16. Iuliano L, Pratico D, Greco C et al. Angioplasty increases coronary sinus F2-isoprostane formation: Evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001;37:76-80.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
18. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
19. Nishijima C, Sato S, Hasegawa M et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 2001; 40:406-9.
20. Nishijima C, Sato S, Takehara K. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis. J Rheumatol 2001; 28:1847-51.
21. Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
22. Montuschi P, Ciabattoni G, Paredi P et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158:1524-7.
23. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32:54-60.
24. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974;53:1-46.
25. Peng SL, Fatenejad S, Craft J. Scleroderma: A disease related to damaged proteins? Nat Med 1997;3:276-8.